List of Excipients in Branded Drug APRETUDE

APRETUDE Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

APRETUDE is a long-acting injectable formulation of cabotegravir, an integrase strand transfer inhibitor used for HIV-1 pre-exposure prophylaxis. Its commercial value depends on maintaining a two-month dosing interval, reliable intramuscular depot behavior, and practical administration by health-care professionals. The excipient system is commercially important because it supports suspension stability, drug loading, injection performance, and refrigerated shelf life.

The formulation creates more development difficulty than the individual excipients. Poloxamer 338, mannitol, phosphate buffer, sodium hydroxide, and water are established pharmaceutical materials, but reproducing cabotegravir particle attributes, sterile processing, resuspendability, and injection force creates the principal barrier to competition.

What excipients are used in APRETUDE?

APRETUDE is supplied as a 600 mg/3 mL extended-release injectable suspension, equivalent to 200 mg/mL of cabotegravir. The product is administered by intramuscular injection in the gluteal muscle, usually once every two months after the initiation regimen (U.S. Food and Drug Administration [FDA], 2024).

Component	Function in formulation	Commercial relevance
Cabotegravir	Active pharmaceutical ingredient	Provides sustained systemic exposure from the injectable depot
Poloxamer 338	Nonionic surfactant and suspension stabilizer	Controls particle wetting, aggregation, and resuspendability
Mannitol	Tonicity and bulking agent	Supports osmolality and suspension properties
Sodium dihydrogen phosphate monohydrate	Buffer component	Helps control formulation pH
Sodium hydroxide	pH adjustment	Supports target pH during manufacture
Water for injection	Vehicle	Sterile continuous phase for the injectable suspension

The label identifies the product as a white to light pink, extended-release injectable suspension. It requires storage at 2°C to 8°C and protection from freezing. These conditions affect logistics, inventory management, and the commercial value of alternative room-temperature formulations (FDA, 2024).

Why is poloxamer 338 strategically important?

Poloxamer 338 is the main formulation excipient with a direct role in suspension performance. It can improve wetting of hydrophobic drug particles and reduce uncontrolled aggregation. For a high-concentration injectable suspension, the supplier’s control of molecular-weight distribution, impurity profile, endotoxin, bioburden, and lot-to-lot consistency is commercially significant.

A generic manufacturer cannot assume that substituting another poloxamer or surfactant will preserve the same injection and pharmacokinetic profile. A change may alter:

• Particle aggregation during storage
• Sedimentation rate
• Syringeability and injection force
• Drug release from the intramuscular depot
• Local tolerability
• Resuspension time before administration
• Exposure variability between doses

This creates opportunities for qualified excipient suppliers with injectable-grade poloxamer capacity and robust regulatory documentation.

How does the APRETUDE formulation create commercial barriers?

The key barrier is formulation reproducibility, not excipient scarcity. APRETUDE uses a high drug concentration in an aqueous suspension. The manufacturing process must control particle size, crystal form, surface properties, dispersion, sterility, and container compatibility.

Relevant development parameters include:

1. Cabotegravir particle-size distribution and morphology.
2. Wetting and dispersion during compounding.
3. Sedimentation and redispersibility during shelf life.
4. Sterile filtration or aseptic processing strategy.
5. Needle passage and injection force.
6. Long-term chemical and physical stability.
7. In-use handling after removal from refrigeration.
8. Consistent release from the injection site.

The excipient list is short, which can simplify regulatory assessment. It also limits opportunities to design around the product through simple ingredient substitution. A competing formulation would likely need a different particle-engineering approach, delivery technology, or manufacturing process.

What formulation patents may protect APRETUDE?

Patent protection for APRETUDE may cover several layers rather than only the named excipients:

Potential protection layer	Typical subject matter	Competitive effect
Cabotegravir compound patents	Chemical structure, salts, stereochemistry, or active forms	Can delay entry of products using the same active ingredient
Long-acting injectable patents	Particle size, crystalline form, depot behavior, or injectable composition	Can block close formulation copies
Manufacturing patents	Milling, precipitation, crystallization, sterilization, or suspension processing	Can force competitors to develop a non-infringing process
Method-of-use patents	HIV pre-exposure prophylaxis, dosing schedules, or patient populations	Can restrict labeled commercial use
Device and administration patents	Injection systems, needle configuration, or administration procedures	May affect delivery alternatives
Packaging and stability patents	Container closure, storage conditions, or reconstitution and handling	Can raise development and supply-chain costs

The Orange Book is the principal source for patents listed against the approved NDA. Patent expiry must be assessed patent by patent because expiration can differ across compound, formulation, method-of-use, and manufacturing claims (FDA, 2024b). FDA approval and patent expiry are separate events.

What is the Orange Book status of APRETUDE?

APRETUDE is an FDA-approved small-molecule product marketed by ViiV Healthcare. Orange Book review should distinguish:

• The APRETUDE NDA and its listed patents.
• Earlier cabotegravir products, including VOCABRIA.
• Patents listed against other cabotegravir products.
• Pediatric exclusivity, if granted.
• Patent-term extensions or regulatory exclusivity.
• The dosage form and route covered by each listed patent.

A patent listed against an oral cabotegravir product does not automatically establish infringement by an injectable product. Conversely, an injectable formulation patent may have limited relevance to an alternative oral or implantable formulation.

When does APRETUDE lose regulatory exclusivity?

APRETUDE received FDA approval on December 20, 2021, for pre-exposure prophylaxis in adults and adolescents weighing at least 35 kg who are at risk of sexually acquiring HIV-1 (FDA, 2021).

Cabotegravir’s regulatory exclusivity must be analyzed across its product history. The active moiety was approved in the United States before APRETUDE through the cabotegravir oral product VOCABRIA. As a result, the relevant NCE exclusivity period is tied to the first U.S. approval of cabotegravir, not automatically reset by the later APRETUDE approval.

Event	Date or status
First U.S. approval of cabotegravir-containing product	January 2021, VOCABRIA
APRETUDE FDA approval	December 20, 2021
Dosing interval	Every two months after initiation
NCE exclusivity impact	Generally linked to first approval of the active moiety
Patent expiry	Requires patent-by-patent Orange Book and patent-term review
Generic pathway	ANDA, subject to applicable patents and exclusivity
Biosimilar pathway	Not applicable; cabotegravir is a small molecule

A later injectable formulation may receive separate protection for formulation or clinical data, but approval of a new dosage form does not necessarily provide a new five-year NCE period. Commercial entry therefore depends more heavily on patents, data exclusivity, formulation differentiation, and the ability to establish bioequivalence or therapeutic equivalence.

Are biosimilars a risk for APRETUDE?

No. APRETUDE is a chemically synthesized small molecule, so a competitor would generally pursue an abbreviated new drug application rather than a biosimilar application under the Public Health Service Act.

The practical competitive risks are:

• An ANDA for a cabotegravir injectable.
• A 505(b)(2) application using a modified long-acting formulation.
• An alternative cabotegravir dosage form.
• An oral or implantable pre-exposure prophylaxis product.
• A different long-acting HIV prevention medicine.

A conventional injectable generic may face substantial development challenges if the reference product’s clinical performance depends on complex particle attributes or depot behavior. A 505(b)(2) applicant could pursue a different formulation, but that route may require additional clinical evidence and may not obtain the same dosing schedule.

What Paragraph IV challenges could affect APRETUDE?

A Paragraph IV certification could challenge Orange Book-listed patents before their stated expiration dates. The most commercially important targets would likely be:

1. Composition-of-matter patents covering cabotegravir.
2. Long-acting injectable composition patents.
3. Particle-size or crystalline-form claims.
4. Dosing-regimen claims for HIV prophylaxis.
5. Manufacturing claims that a generic process may practice.

A successful Paragraph IV challenge could accelerate entry. A failed challenge, an infringement finding, or a settlement could preserve the reference product’s market position. The 30-month stay provisions, patent listing dates, and any pediatric exclusivity would affect the timing.

No specific litigation outcome should be inferred solely from FDA approval records. Litigation and settlement analysis requires review of district court filings, Federal Circuit decisions, ANDA notices, and ViiV or GSK securities disclosures.

What commercial opportunities exist for APRETUDE excipient suppliers?

Injectable-grade poloxamer supply

The clearest excipient opportunity is supply of poloxamer 338 meeting injectable-grade specifications. A supplier with multiple qualified manufacturing sites, low endotoxin performance, and strong change-control documentation could compete for:

• Primary APRETUDE supply.
• Regional contract manufacturing.
• Generic cabotegravir development.
• Clinical-stage long-acting antivirals.
• Other nanosuspension and depot products.

Supplier qualification may be difficult because switching excipient sources can trigger comparability work, stability studies, process validation, and regulatory filings.

Alternative surfactant systems

Companies developing a competing cabotegravir formulation could evaluate other nonionic surfactants, phospholipids, polymeric stabilizers, or surface-modified particles. The commercial objective would be to match APRETUDE’s pharmacokinetics while avoiding formulation claims.

The main risks are local tolerability, altered drug release, injection-site reactions, and regulatory comparability. A new surfactant system could also produce a distinct patent estate if it improves storage stability, reduces injection volume, or enables room-temperature storage.

Room-temperature or extended-stability products

APRETUDE requires refrigerated storage. A formulation that remains stable at controlled room temperature could reduce distribution costs and expand use in lower-resource settings. Potential approaches include:

• Improved crystal-form control.
• Surface modification of cabotegravir particles.
• Lyophilized or solid-injection systems.
• Alternative aqueous vehicles.
• Polymer or lipid depots.
• More robust container-closure systems.

A room-temperature product would need to demonstrate chemical stability, physical stability, sterility assurance, dose uniformity, and equivalent clinical exposure.

Reduced injection volume

APRETUDE delivers 600 mg in 3 mL. A higher drug-loading formulation or more efficient depot system could reduce injection volume and improve administration convenience. This opportunity is technically difficult because increased concentration can raise viscosity, aggregation, injection force, and local tissue burden.

Delivery-device and administration opportunities

APRETUDE is administered by a health-care professional. Commercial opportunities include:

• Pre-filled syringe systems.
• Needles optimized for suspension delivery.
• Closed-transfer and dose-preparation systems.
• Training tools for ventrogluteal administration.
• Cold-chain monitoring and inventory systems.
• Clinic workflow software tied to two-month dosing.

Device patents may create additional freedom-to-operate considerations even where the formulation itself is non-infringing.

How does APRETUDE compare with oral PrEP products?

Attribute	APRETUDE	Oral TDF/FTC PrEP
Active modality	Long-acting cabotegravir injectable	Daily oral antiretroviral
Administration	Intramuscular injection by a health-care professional	Patient self-administration
Dosing frequency	Every two months after initiation	Daily
Cold-chain requirement	Refrigerated storage	Generally simpler storage
Adherence model	Clinic-controlled dosing	Patient-dependent adherence
Formulation complexity	High	Lower
Generic substitution risk	Delayed by injectable formulation and patents	More established generic competition
Operational burden	Injection visits and scheduling	Prescription refill and daily adherence

Clinical trials found cabotegravir injections superior to daily oral TDF/FTC in preventing HIV acquisition in studied populations, including a 66% lower incidence in HPTN 083 and an 89% lower incidence in HPTN 084 (Landovitz et al., 2021; Delany-Moretlwe et al., 2022). The commercial tradeoff is between adherence protection and the infrastructure required for repeated injections.

What generic launch scenarios exist for APRETUDE?

Scenario 1: Delayed injectable generic entry

A generic company waits for key formulation and compound patents to expire, then develops a close suspension equivalent. This is the least disruptive scenario but may still require extensive analytical and clinical work.

Scenario 2: Paragraph IV challenge

A well-capitalized generic manufacturer challenges formulation or method-of-use patents. The outcome depends on claim scope, validity, infringement, and settlement terms.

Scenario 3: 505(b)(2) alternative depot

A competitor develops a different cabotegravir injectable, implant, or extended-release system. This could avoid some listed patents but would require a differentiated regulatory package.

Scenario 4: Therapeutic replacement

A competitor does not copy cabotegravir. Instead, it introduces another long-acting HIV prevention product with improved storage, administration, or dosing. This creates substitution risk before APRETUDE faces direct generic competition.

How strong is the APRETUDE patent and formulation estate?

The estate is strongest where multiple protection layers overlap: active ingredient, long-acting injectable composition, particle engineering, manufacturing, dosing, and HIV prevention use. It is weaker where protection depends only on conventional excipients that can be substituted without changing the active product profile.

The principal strength indicators are:

• Broad claims covering cabotegravir injectable suspensions.
• Valid claims tied to particle properties or depot release.
• Manufacturing claims difficult to design around.
• Long patent terms remaining after regulatory approval.
• Separate protection for prevention dosing and administration.
• Limited availability of clinically validated alternatives.

The principal weaknesses are the established nature of the excipients, the small-molecule ANDA pathway, the possibility of non-infringing particle-engineering approaches, and the lack of biosimilar-style clinical barriers.

Key Takeaways

• APRETUDE uses cabotegravir, poloxamer 338, mannitol, sodium dihydrogen phosphate monohydrate, sodium hydroxide, and water for injection.
• Poloxamer 338 is the most strategically important named excipient because it supports suspension stability and injection performance.
• The main competitive barrier is the integrated formulation and manufacturing process, not the individual excipients.
• APRETUDE is a small molecule and faces generic, not biosimilar, competition.
• FDA approval occurred on December 20, 2021, but cabotegravir’s first U.S. approval predates APRETUDE, limiting the likelihood of a new NCE exclusivity period.
• Commercial opportunities include injectable-grade excipient supply, alternative surfactant systems, room-temperature formulations, reduced-volume injections, and administration devices.
• Generic entry could occur through a close injectable equivalent, a Paragraph IV challenge, or a 505(b)(2) alternative depot.
• The most valuable patent claims are likely those covering cabotegravir’s long-acting particle system, manufacturing process, depot behavior, and prevention dosing.

FAQs

Can poloxamer 338 be replaced in an APRETUDE generic?

Potentially, but replacement would require proof that the alternative stabilizer preserves particle size, resuspendability, injection performance, release behavior, and clinical exposure.

Is APRETUDE a biologic drug?

No. APRETUDE is a chemically synthesized small-molecule drug containing cabotegravir.

Can APRETUDE be stored at room temperature?

The U.S. label specifies refrigerated storage at 2°C to 8°C and instructs users not to freeze the product. A room-temperature alternative would require separate stability and regulatory support (FDA, 2024).

What is the largest excipient-related opportunity around APRETUDE?

The largest opportunity is injectable-grade poloxamer 338 supported by reliable supply, low endotoxin performance, regulatory documentation, and change-control capability.

Could an implant compete with APRETUDE?

Yes. An implantable cabotegravir or alternative long-acting HIV prevention product could compete by reducing clinic visits or extending dosing intervals, but it would require a new delivery system, clinical development, and a separate patent and regulatory strategy.

References

1. Delany-Moretlwe, S., Hughes, J. P., Bock, P., et al. (2022). Long-acting injectable cabotegravir for HIV prevention in women. The New England Journal of Medicine, 386(26), 2563-2574. https://doi.org/10.1056/NEJMoa2116035

2. Food and Drug Administration. (2021). FDA approves first injectable treatment for pre-exposure prevention of HIV. https://www.fda.gov/news-events/press-announcements/fda-approves-first-injectable-treatment-pre-exposure-prevention-hiv

3. Food and Drug Administration. (2024a). APRETUDE (cabotegravir extended-release injectable suspension) prescribing information. ViiV Healthcare.

4. Food and Drug Administration. (2024b). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/

5. Landovitz, R. J., Donnell, D., Clement, M. E., et al. (2021). Cabotegravir for HIV prevention in cisgender men and transgender women. The New England Journal of Medicine, 385(7), 595-608. https://doi.org/10.1056/NEJMoa2101016